Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSibylle Loibl, Nadia Harbeck, Lucia Del Mastro et al.|Annals of Oncology|2023Cited by 830
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Klaus Pantel, Jean‐Yves Pierga et al.|Critical Reviews in Oncology/Hematology|2018Cited by 268
Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatmentNicholas C. Turner, François‐Clément Bidard, Cynthia Huang Bartlett et al.|Future Oncology|2023Cited by 78
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trialWolfgang Janni|BMC Cancer|2016Cited by 17
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design SimulationLorenzo Gerratana, Massimo Cristofanilli, Jean‐Yves Pierga et al.|The Oncologist|2022Cited by 13